ESMO Immuno-Oncology Congress 2025

Start:

Wed, 10 Dec 2025, 09:00

End:

Fri, 12 Dec 2025, 04:00

Website:

https://iii.hm/esmoioc25

Venue:

Find ESMO On Social Media

Exhibit

Symposia

Workshops

Organiser

Sponsor

Save the date for the ESMO Immuno-Oncology Congress 2025, taking place from 10 until 12 December 2025 as an onsite event in London, UK, as well as online.

This international event provides valuable knowledge: from basic science to translational research and clinical development, cutting-edge science, and excellent networking opportunities.

Take part in this meeting to learn, share your research and expertise and connect with the stakeholders that are making a difference in the field.

ESMO Immuno-Oncology Congress 2025 Scientific Co-Chairs

Aurélien Marabelle

Villejuif
France

Inge Marie Svane

Copenhagen
Denmark

Sergio Quezada

London
United Kingdom

The ESMO Immuno-Oncology Congress 2025 will take place from 10 to 12 December 2025 in London, United Kingdom, with sessions available also through a dedicated platform.

Registration includes:

Participation in scientific and educational sessions
Opportunities to network with speakers, faculty and peers
Access to the poster area
Interaction with industry partners in the exhibition area
Participation in the Industry Satellite Symposia
Live-streamed sessions and sessions on-demand on the virtual congress platform
Access to the meeting resources on OncologyPRO after the event
The ESMO Daily Reporter
Coffee breaks and lunches

Registration fees and deadlines

Individual registration will remain open for the duration of the congress. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO membership must be active ten (10) working days prior to the registration, to be eligible for the reduced member registration fee. Please visit the membership pages on esmo.org to check eligibility criteria, benefits, and to complete the membership application.

Registration fees (20% British VAT included)	Early registration until 8 October 2025	Late registration until 12 November 2025	Full registration from 13 November 2025
ESMO Member	€ 480.00	€ 570.00	€ 730.00
ESMO Member Developing Countries*	€ 200.00	€ 230.00	€ 365.00
ESMO Member in Training**	€ 200.00	€ 230.00	€ 270.00
ESMO Member Undergraduate Student	€ 200.00	€ 230.00	€ 270.00
ESMO Member Patient Advocate	€ 200.00	€ 230.00	€ 270.00
ESMO Member Nurse	€ 200.00	€ 230.00	€ 270.00
Non-Member Academia & Other (non-Industry)***	€ 725.00	€ 840.00	€ 945.00
Non-Member Industry & Commercial****	€ 1,010.00	€ 1,122.00	€ 1,240.00

* Applicable to ESMO members from developing countries only.
At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.

** ESMO members must be under 40 and in training to qualify for this fee.

*** Applicable to individuals working in: Hospitals, Universities, CRO's, Private Practice, Labs, NGO’s, Non-profits, Cancer Patient Advocacy Groups and Gov't Agencies

**** Applicable to individuals working in Pharmaceutical / Biotechnology Companies, Service Providers, Consultancies, Financial Institutions, Marketing & Communications Companies, Management and Data Companies and Training & Education Companies.

Register Now

The ESMO Immuno-Oncology Congress 2025 programme is online!

Access the Programme online

Learning objectives

Access immersion sessions in immunobiology and immuno-oncology translational research insights
Review state of the art, checkpoint inhibitor-based therapeutic strategies in immuno-oncology
Understand recent developments in immune modulation, including tumour microenvironment, immunometabolism, epigenetics and cell signalling
Connect with Industry and independent investigators for an overview of research and development in immuno-oncology, including cellular therapies, vaccines and immune modulators, intratumoural immunotherapy and multispecific constructs

Accreditation

ESMO-MORA: The ESMO Immuno-Oncology 2025 programme will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.